Share：
Share this content in WeChat
X
[Chinese][PDF]784104
• Review •
Progress in magnetic resonance imaging of glioma IDH genotype
YAN Haili  ZHANG Hui 

Cite this article as: Yan HL, Zhang H. Progress in magnetic resonance imaging of glioma IDH genotype. Chin J Magn Reson Imaging, 2019, 10(6): 452-455. DOI:10.12015/issn.1674-8034.2019.06.012.


[Abstract] IDH gene mutations exist in 70%-80% of grade Ⅱ-Ⅲ gliomas and 90% of secondary glioblastomas. Growing data indicate that IDH mutations play prominent roles in the occurrence of glioma, biological behavior, and also have clinical and prognostic importance. At the same time, IDH genotypes as an important biomarker can help to find possible targets for the treatment of glioma and achieve accurate diagnosis or treatment of tumors. Current methods for detecting glioma IDH genes include invasive immunohistochemistry and genetic testing. In recent years, with the development of multimodal MRI, imaging studies have penetrated into the fields of radiomics and radiogenomics. The preoperative non-invasive evaluation of IDH genotype by imagings is of great significance for the individualized accurate diagnosis and treatment of glioma. Researchers have explored the link between imaging features and tumor gene phenotypes. Functional magnetic resonance imaging is increasingly used for preoperative detection of IDH genotype in glioma. This paper will summarize the IDH mutations in gliomas and will review recent progress of noninvasive assessment IDH genotype in glioma by functional magnetic resonance imaging.
[Keywords] glioma；functional magnetic resonance imaging；IDH genotype

YAN Haili Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China

ZHANG Hui* Department of Radiology, the First Hospital of Shanxi Medical University, Taiyuan 030001, China

*Correspondence to: Zhang H, E-mail: zhanghui_mr@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of National Natural Science Foundation of China No. 81771824, 81471652 Social Development Projects of Key R&D Program in Shanxi Province No. 201703D321016
Received  2018-11-13
Accepted  2018-12-19
DOI: 10.12015/issn.1674-8034.2019.06.012
Cite this article as: Yan HL, Zhang H. Progress in magnetic resonance imaging of glioma IDH genotype. Chin J Magn Reson Imaging, 2019, 10(6): 452-455. DOI:10.12015/issn.1674-8034.2019.06.012.

[1]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol, 2016, 131(6): 803-820.
[2]
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897): 1807-1812.
[3]
Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol, 2010, 120(6): 707-718.
[4]
Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol, 2014, 16(1): 81-91.
[5]
Qi S, Yu L, Gui S, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci, 2012, 103(2): 269-273.
[6]
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol, 2009, 118(4): 469-474.
[7]
Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol, 2011, 29(34): 4482-4490.
[8]
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 462(7274): 739-744.
[9]
Koivunen P, Lee S, Duncan C, et al. Transformation by the (R)- enantiomer of 2-hydroxyglutarate linked to EglN activation. Nature,2012, 483(7390): 484-488.
[10]
Ma R, Yun CH. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochem Biophys Res Commun, 2018, 503(4): 2912-2917.
[11]
Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol, 2012, 107(1): 197-205.
[12]
Choi C, Raisanen JM, Ganji SK, et al. Prospective longitudinal analysis of 2-Hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma. J Clin Oncol, 2016, 34(33): 4030-4039.
[13]
De la Fuente MI, Young RJ, Rubel J, et al. Integration of 2- hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol, 2016, 18(2): 283-290.
[14]
Natsumeda M, Igarashi H, Nomura T, et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun, 2014, 2: 158.
[15]
Emir UE, Larkin SJ, De Pennington ND, et al. Non-invasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. Cancer Res, 2016, 76(1): 43-49.
[16]
Berrington A, Voets NL, Plaha P, et al. Improved localisation for 2-hydroxyglutarate detection at 3T using long-TE semi-LASER. Tomography, 2016, 2(2): 94-105.
[17]
Kickingereder P, Sahm F, Radbruch, A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep, 2015, 5: 16238.
[18]
Tan W, Xiong J, Huang W, et al. Noninvasively detecting isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging, 2017, 45(2): 492-499.
[19]
Leu K, Ott GA, Lai A, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade Ⅱ-Ⅲ diffuse gliomas. J Neurooncol, 2017, 134(1): 177-188.
[20]
Liu T, Cheng G, Kang X, et al. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging. Neuroradiology, 2018, 60(7): 693-702.
[21]
Xing Z, Yang X, She D, et al. Noninvasive assessment of IDH mutational status in World Health Organization grade Ⅱ and III astrocytomas using DWI and DSC-PWI combined with conventional MR Imaging. AJNR Am J Neuroradiol, 2017, 38(6): 1138-1144.
[22]
Tan W, Huang W, Yin B, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol, 2014, 35(5): 920-927.
[23]
Xiong J, Tan WL, Pan JW, et al. Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density. J Magn Reson Imaging, 2016, 43(1): 45-54.
[24]
Xiong J, Tan W, Wen J, et al. Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol, 2016, 26(6): 1705-1715.
[25]
Eichinger P, Alberts E, Delbridge C, et al. Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade Ⅱ/Ⅲgliomas. Sci Rep, 2017, 7(1): 13396.
[26]
Hempel JM, Bisdas S, Schittenhelm J, et al. In vivo molecular profiling of human glioma using diffusion kurtosis imaging. J Neurooncol, 2017, 131(1): 93-101.
[27]
Bai Y, Lin Y, Zhang W, Kong L, et al. Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas. Oncotarget, 2017, 8(4): 5834-5842.
[28]
Jiang S, Yu H, Wang X, et al. Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla. Eur Radiol, 2016, 26(1): 64-71.
[29]
Ma B, Blakeley JO, Hong X, et al. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging, 2016, 44(2): 456-462.
[30]
Doll S, Urisman A, Oses-Prieto JA, et al. Quantitative proteomics reveals fundamental regulatory differences in oncogenic HRAS and isocitrate dehydrogenase (IDH1) driven astrocytoma. Mol Cell Proteomics, 2017, 16(1): 39-56.
[31]
Jiang S, Zou T, Eberhart CG, et al. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Magn Reson Med, 2017, 78(3): 1100-1109.
[32]
Paech D, Windschuh J, Oberhollenzer J, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol, 2018, 20(12): 1661-1671.

PREV The fourth ventricle central neurocytoma: A case report
NEXT Research progress of MRI neuroimaging in HIV-associated neurocognitive disorders
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn